Navigation Links
Empire Genomics Licenses Novel DNA Biomarker for Use in Diagnosing and Creating a Companion Diagnostic Test for Neuroendocrine Prostate Cancer
Date:5/22/2013

BUFFALO, N.Y., May 22, 2013 /PRNewswire/ -- Empire Genomics announced today it has acquired an exclusive license for a patent pending novel genomic biomarker from Cornell University for use in developing a molecular diagnostic test that could help in diagnosing and determining treatment for patients with neuroendocrine (NEPC) prostate cancer. 

Neuroendocrine prostate cancer (NEPC) is a lethal variant of prostate adenocarcinoma (PCA) that can arise de novo, but more commonly arises after hormonal therapy for PCA. Little is known about the underlying molecular biology of NEPC or how and why some patients with PCA progress to a predominantly neuroendocrine phenotype. There is currently no effective therapy for NEPC, and most patients survive less than one year. The poor molecular characterization of NEPC accounts in part for the lack of disease specific therapeutics.

"Each year, approximately, 30,000 men will die of advanced prostate cancer, most of whom will be treated with androgen suppression therapy, however, it is impossible to know just how many of them developed NEPC because patients are not typically biopsied at that stage of their disease," said Dr. Brian Kelly , Director of Technology Commercialization and Liaison at the Weill Cornell Medical College office of the Cornell Center for Technology Enterprise and Commercialization (CCTEC). "We are delighted that Empire Genomics is now going to make this important diagnostic test available to this patient population and we look forward to working with the company and its seasoned management team."

"We are delighted to work with Empire Genomics to help develop a commercial grade assay to test for abnormalities one of the key driving genes of the most aggressive form of prostate cancer.  This clinical tool will be important as we move forward with precision medicine clinical trials for aggressive castration resistant prostate cancer lead by Dr. Himisha Beltran," said Mark Rubin , Homer T. Hirst Professor of Pathology in Oncology and the Director of the Institute for Precision Medicine.

Empire Genomics will launch a genetic test for NEPC that will diagnose NEPC Prostate Cancer later this year and seek to partner with pharmaceutical companies to use this assay for accelerating patient stratification in clinical trials. 

"We are very pleased to work with Drs. Rubin and Beltran and Cornell to commercialize this technology," said Anthony Johnson , CEO of Empire Genomics. "It is another exciting genomic tool that we have added to our exclusive precision medicine portfolio."

About Empire Genomics

Empire Genomics LLC is a firm in the field of molecular genomic testing specializing in oncology.  The company offers a wide range of best in class services that are used to detect genomic changes. The firm is a leader in the field of personalized medicine and helps clinicians, drug developers and researchers answer key questions in disease diagnosis, disease prognosis, and determining treatment for diseases. 

Contact:

Sonya Stutts

716-856-3873

This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Empire Genomics, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Research Alert -- Empire Asset Management Co. Initiates Coverage on Exact Sciences (NASDAQ: EXAS)
2. J. Craig Venter Institutes Mobile Genomics Lab Launches First School Visits in San Diego County
3. Real Time Genomics Secures a $5 Million Round of Funding to Expand Commercial Operations
4. Real Time Genomics and Knome Ink Deal to Integrate and Sell the RTG Variant Platform on knoSYS100 System
5. Real Time Genomics and J. Craig Venter Institute Embark on Strategic Research Initiative
6. Nimbix and Convey Partner for “The Accelerated Genomics Cloud” (TAGC) Promotion
7. Rosetta Genomics Reaches Settlement Agreement with Sanra Laboratories in Connection with Previous Sale of Parkway Clinical Laboratories
8. Real Time Genomics and Omicia Partner on a Platform for Integrated Genomic Analysis for Childhood Disease
9. Venter Institute-Led Team Recovers and Sequences Genome of Periodontal Pathogen from Biofilm in Hospital Sink using Single-Cell Genomics
10. Rosetta Genomics Announces Poster Presentations at AACR Annual Meeting 2013
11. Squished bug genomics: Insect goo aids biodiversity research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... Amendia, Inc., a leading ... today announced the completion of a significant transaction and partnership that positions Amendia ... and partners. Kohlberg & Company, L.L.C. (“Kohlberg”), a leading private equity firm ...
(Date:4/29/2016)... ... April 29, 2016 , ... Summit for Stem Cell has received a ... a patient-specific stem cell therapy for the treatment of Parkinson’s disease. The Summit research ... at The Scripps Research Institute in San Diego, CA. , The aim ...
(Date:4/28/2016)... PUNE, India , April 28, 2016 ... PT, JT, Stirling, and Brayton Cryocoolers), Service (Technical Support, ... Application, and Geography - Global Forecast to 2022", published ... to USD 2.94 Billion by 2022, at a CAGR ... Browse 70 market data Tables and 94 Figures spread ...
(Date:4/28/2016)... Boston, MA (PRWEB) , ... April 28, 2016 ... ... (EDT), Asymmetrex will deliver a talk on its first-in-class technologies for ... the 2016 Meeting on RNAiMicroRNA Biology to Reprogramming & CRISPR-based Genome ...
Breaking Biology Technology:
(Date:5/3/2016)... 2016  Neurotechnology, a provider of high-precision biometric ... Biometric Identification System (ABIS) , a complete system ... ABIS can process multiple complex biometric transactions with ... fingerprint, face or iris biometrics. It leverages the ... MegaMatcher Accelerator , which have been used ...
(Date:4/28/2016)... and BANGALORE, India , April 28, ... Systems, a product subsidiary of Infosys (NYSE: INFY ... announced a global partnership that will provide end ... use mobile banking and payment services.      (Logo: ... key innovation area for financial services, but it also plays ...
(Date:4/28/2016)... , April 28, 2016 First quarter ... (139.9), up 966% compared with the first quarter of 2015 ... totaled SEK 589.1 M (loss: 18.8) and the operating margin was ... (loss: 0.32) Cash flow from operations was SEK 249.9 ... 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. The ...
Breaking Biology News(10 mins):